SEC levies no fine against Kiromic BioPharma after material omissions self-disclosure
By 
Aaron Nicodemus2024-12-03T17:48:00
Kiromic BioPharma will pay no fine to the Securities and Exchange Commission (SEC) after self-reporting that it failed to disclose material information about two cancer drugs to investors.
Houston-based Kiromic raised $40 million in a July 2021 public offering to fund clinical trials for two cancer drugs, but failed to alert investors that the U.S. Food and Drug Administration (FDA) had placed holds on clinical trials two weeks before the offering, the SEC said Tuesday in a press release. The company failed to report the FDA holds in two SEC filings, and failed to correct statements made by executives in roadshow calls with investors, according to the agency.
The allegations came to light after two anonymous complaints were filed on the company’s whistleblower hotline in August 2021, the SEC said.
Related articles
-
WebcastWebcast: The DOJ’s Corporate Whistleblower Program: What we’ve learned and how it can change in the future
We will discuss the critical role whistleblowers play in law enforcement, and how the DOJ has structured its program to incentivize people to come forward.
-
News BriefTeva Pharma to pay $450M to settle kickback, price-fixing allegations
Generic drug giant Teva Pharmaceuticals has agreed to pay $450 million to settle two cases brought by the Department of Justice (DOJ), including one alleging that co-pays it made on behalf of Medicare patients constituted illegal kickbacks, and a second action for alleged generic drug price fixing.
-
ArticlePharma, whistleblower lessons learned from $900M Biogen settlement
Experts discuss the ramifications of Biogen’s $900 million settlement for False Claims Act violations, including the $266.4 million whistleblower bounty in the case believed to be the largest single award under any government program.
More from Regulatory Enforcement
-
ArticleNY auto insurers on the hook for $19M for cybersecurity violations
Eight auto insurers failed to meet the requirements of New York’s cybersecurity regulations during widespread online attacks in 2021 and will pay $19 million under consent orders with the New York State Department of Financial Services (NYDFS).
-
News BriefCanada to launch new federal office targeting financial crime and fraud
Canada is creating a new federal office to lead efforts against financial crime. The initiative marks the government’s most significant move yet to modernize its approach to fraud and money laundering.
-
News BriefSmartmatic faces DOJ charges amid allegations of election contract bribes
Three executives of a multinational voting machine company in the crosshairs of President Donald Trump since 2020 have been indicted in Florida by the U.S. Department of Justice for allegedly paying $1 million in bribes to the Philippines top election official.